X4 Pharmaceuticals Narrows Q3 Loss to 16c/Share, Cash at $187.7M
XFOR sits 33% above its 52-week low of $2.43.
Summary
X4 posted a Q3 loss of 16 cents a share, narrowing the quarterly net loss to $20.2M from $29.8M a year earlier. The company ended September with $187.7M in cash and securities, a cushion that covers the 4WARD Phase 3 program and the recently restructured debt. The 10-Q filed minutes before this wire also spells out the October K2 HealthVentures refinancing, including a $15M convertible component, so the balance sheet now carries a $150M senior secured term loan. The quarter's story is spending discipline plus a funded pipeline rather than a revenue surprise — mavorixafor in chronic neutropenia remains pre-commercial. The FDA's September agreement to cut 4WARD enrollment from 176 to 126 patients keeps the trial timeline intact, and X4 expects the 4WARD enrollment target in Q4 2026; trial execution and enrollment are the items that will drive the stock from here.
At the time of this announcement, XFOR was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.2M. The 52-week trading range was $2.43 to $4.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.